News and Announcements
Further strong progress in CAVATAK™ phase 2 CALM trial
- Published November 08, 2013 11:10AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
ASX and Media Release, 8 November 2013, Sydney, Australia
iralytics Limited (ASX:VLA, OTC:VRACY) continues to make strong progress on its Phase 2 clinical trial of CAVATAK™ in the treatment of late stage melanoma patients (the CALM study).
To read the full announcement please click on the document below.